Array BioPharma Inc. F3Q 2010 (Qtr End 06/30/2010) Earnings Call Transcript

Array BioPharma Inc (ARRY)

F3Q 2010 (Qtr. End 06/30/2010) Earnings Call

May 4, 2010 9:00 a.m. ET

Executives

Tricia Haugeto - IR

Bob Conway - CEO

Mike Carruthers - CFO

Kevin Koch - President and Chief Scientific Officer

David Snitman - COO and VP, Business Development

Analysts

Howard Liang - Leerink Swann

Ted Tenthoff - Piper Jaffray & Co.

John Sonnier - William Blair

Simos Simeonidis - Rodman & Renshaw

Stephen Willey - Thomas Weisel Partners

Presentation

Operator

Compare to:
Previous Statements by ARRY
» Array BioPharma Inc. F2Q10 (Qtr End 12/31/09) Earnings Call Transcript
» Array BioPharma Inc. F1Q10 (Quarter Ended June 30, 2010) Earnings Call Transcript
» Array BioPharma F2Q09 (Qtr End 12/31/08) Earnings Call Transcript

Good day, everyone, and welcome to today's Array BioPharma third quarter fiscal 2010 financial results conference; just a reminder that today's call is being recorded. At this time for opening remarks I would like to turn the call over to Ms. Tricia Haugeto. Please go ahead, ma'am.

Tricia Haugeto

Thank you, [Lisa]. Good morning and welcome once again to Array BioPharma's conference call to discuss our financial results for the third quarter of fiscal 2010. You can listen to this conference call on Array's website at www.arraybiopharma.com. In addition a replay of the conference call will be available via telephone for the next seven days and via the internet.

I'd like to introduce Array's Chief Executive Officer, Bob Conway and our Chief Financial Officer, Mike Carruthers, who will lead the call today. I'd also like to introduce Kevin Koch, our President and Chief Scientific Officer and David Snitman, our Chief Operating Officer and Vice President of Business Development, who will be available to answer questions as needed.

But before I hand over the call to Bob, I would like to read the following Safe Harbor statement. The matters we are discussing today include projections or other forward-looking statements about the future results, research and development goals of Array and its collaborators and future financial performance of Array. These statements are estimates based on management's current expectations and involve risks and uncertainties that could cause them to differ materially from actual results.